Ischemic Priapism After a Penile Injection: Phenylephrine, the Shunt, and What Comes After
A single patient presenting with acute ischemic priapism after his usual home injection, arriving with blood pressure already elevated before any treatment starts. The disagreement isn't the first-line therapy — it's how many rounds of it to try, and on whom, before calling it a failure.
Dwayne K., a 49-year-old warehouse operations manager, has used home trimix injections for erectile dysfunction for the past year without incident — until this morning, when what he describes as possibly a larger-than-usual dose left him with a rigid, painful erection that hasn’t resolved after five hours. Cavernous blood gas on arrival confirms what the duration and pain already suggested: hypoxic, hypercarbic, and acidotic, the signature of ischemic, low-flow priapism, a urologic emergency regardless of what triggered it. His blood pressure on arrival, before anyone has given him anything, is already 178/104 — a poorly controlled hypertension history he reports himself, and a number that matters because of what happens next.
First-line treatment for acute ischemic priapism is intracavernosal phenylephrine combined with corporal aspiration and saline irrigation, and the evidence the AUA/SMSNA priapism guideline assembles for combining rather than using phenylephrine alone is specific: subsequent shunt surgery was needed in 15 to 28 percent of men treated with the combination, against 43 to 63 percent of those given intracavernosal phenylephrine without aspiration and irrigation. Phenylephrine is a potent, fairly selective alpha-1 agonist, and administering it intracavernosally to a man whose blood pressure is already elevated is exactly the scenario the guideline’s own safety measure exists for — continuous blood pressure and heart rate monitoring during administration, not because the drug is contraindicated at this pressure, but because a hypertensive man given a systemic alpha-agonist is precisely who that monitoring is meant to protect. What the guideline does not specify is how many rounds of aspiration, irrigation, and phenylephrine constitute a fair pharmacologic trial: it directs a distal corporoglanular shunt for priapism that persists after first-line therapy, without ever defining how many attempts “persists” requires. The guideline reserves its explicit inadequate-evidence-to-quantify language for a later branch — whether a proximal shunt adds anything once a distal one has failed — which leaves the ceiling on pharmacologic attempts not hedged but simply unaddressed. Five hours also sits comfortably inside the window where response is still expected; phenylephrine’s effectiveness is known to fall off as duration approaches roughly forty-eight hours, once ischemia and acidosis have impaired the smooth muscle’s ability to respond at all.
In the emergency department, five hours in
Proceed with aspiration, saline irrigation, and intracavernosal phenylephrine now. Five hours is well inside the window where this combination is expected to work — phenylephrine's effectiveness only meaningfully falls off as duration approaches forty-eight hours, and combination therapy specifically lowers his odds of ending up in the operating room at all.
I'm less comfortable giving repeated doses of a potent alpha-agonist to a man who's already at 178 over 104 before we've given him anything. If his pressure climbs further with each dose, we're trading a urologic emergency for a hypertensive one — I'd rather move to shunt sooner than cycle multiple rounds hoping the next one works.
The guideline's own answer to that exact risk is continuous blood pressure and heart rate monitoring during administration — that's the safeguard built into using phenylephrine here, not a reason to skip a proven first-line therapy before we've even tried it once.
I think you're both right about different parts of this. First-line pharmacologic therapy is genuinely indicated at five hours with his blood pressure this elevated, under monitoring — but the guideline tells us to shunt when priapism persists after first-line therapy without ever saying how many attempts make it persistent — which means the actual failure point is whatever we decide it is right now, not something written down for us.
Set the ceiling explicitly before starting: aspiration, irrigation, and phenylephrine under continuous BP and HR monitoring, and if there's no detumescence after three cycles or sixty minutes, move to a distal shunt without further delay. That gives the pharmacologic approach a real, monitored trial without letting 'try one more round' become an open-ended decision made under pressure.
Agreed: proceed with corporal aspiration, saline irrigation, and graded intracavernosal phenylephrine under continuous blood pressure and heart rate monitoring, with an explicit plan — if no detumescence after three cycles or sixty minutes — to move directly to a distal shunt without further delay.
Not agreed: whether Dwayne can resume home trimix injections once this resolves. The urologist would rather hold ICI therapy entirely and switch him to a different strategy given today’s episode; the pharmacologist sees a single dosing error as insufficient grounds to abandon a regimen that worked without incident for a year, and would instead re-titrate under office supervision once things settle.